You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 6,599,530


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,599,530
Title: Oral compacted composition comprising catechol derivatives
Abstract:The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and croscarmellose sodium. The composition is premised on the discovery that croscarmellose sodium increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of croscarmellose sodium in the composition is at least 6% by weight, preferably from about 8% to about 16% by weight, especially from about 10% to about 14% by weight.
Inventor(s): Vahervuo; Kari (Espoo, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/152,263
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Process; Use;
Patent landscape, scope, and claims:

United States Patent 6,599,530: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 6,599,530, titled "Oral compacted composition comprising catechol derivatives," is a significant patent in the pharmaceutical field, particularly in the development of oral formulations for catechol derivatives. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention Overview

The patent, issued on July 29, 2003, pertains to an oral compacted composition that includes catechol derivatives such as entacapone or nitecapone, or their pharmaceutically acceptable salts. These compounds are used in the treatment of Parkinson's disease and other conditions involving dopamine deficiency[4].

Scope of the Patent

The scope of the patent is defined by its claims, which outline the specific aspects of the invention that are protected. Here are the key elements:

Claims Structure

The patent includes multiple claims, each detailing a specific aspect of the oral compacted composition. These claims can be categorized into independent and dependent claims. Independent claims stand alone and define the broadest scope of the invention, while dependent claims build upon the independent claims and provide additional specificity[4].

Key Claim Elements

  • Active Ingredients: The patent specifies the use of catechol derivatives such as entacapone or nitecapone.
  • Formulation: The composition is described as an oral compacted form, which could be a tablet or capsule.
  • Excipients: The claims mention the inclusion of excipients like crospovidone, which acts as a disintegrant to facilitate the dissolution of the tablet in the mouth or gastrointestinal tract[2][4].

Claim Analysis

Independent Claims

Independent claims are crucial as they define the broadest protection for the invention. For example, Claim 1 might specify the composition comprising entacapone and a disintegrant, while subsequent independent claims might cover variations such as different catechol derivatives or additional excipients.

Dependent Claims

Dependent claims narrow down the scope by adding specific details. For instance, a dependent claim might specify the amount of entacapone or the type of disintegrant used. These claims provide a more detailed description of the invention and help in distinguishing it from prior art.

Patent Landscape

Prior Art and Related Patents

The patent landscape around U.S. Patent 6,599,530 includes other patents related to oral formulations and catechol derivatives. For example, patents like U.S. Patent Application 20080139660A1 discuss the use of croscarmellose sodium as a superior disintegrant in tablets, which is relevant to the formulation described in the patent[2].

Competing Technologies

Competing technologies in the field of Parkinson's disease treatment include other oral formulations and delivery systems. The patent's unique combination of catechol derivatives and specific excipients sets it apart from these competitors.

Patent Quality and Scope Metrics

The quality and scope of the patent can be evaluated using metrics such as independent claim length and count. Research suggests that narrower claims, which are often the result of a more rigorous examination process, are associated with a higher probability of grant and shorter examination times[3].

Examination Process

The examination process for U.S. Patent 6,599,530 would have involved a thorough review of the claims to ensure they are clear, specific, and not overly broad. The patent's issuance indicates that the claims were deemed valid and novel by the U.S. Patent and Trademark Office (USPTO).

Litigation and PTAB Cases

The patent has been involved in various legal proceedings, including cases before the Patent Trial and Appeal Board (PTAB). These cases often challenge the validity or scope of the patent claims, providing additional insight into the patent's strength and the competitive landscape[5].

Industry Impact

The invention described in U.S. Patent 6,599,530 has a significant impact on the pharmaceutical industry, particularly in the treatment of Parkinson's disease. The oral compacted composition offers a convenient and effective delivery method for catechol derivatives, enhancing patient compliance and treatment outcomes.

Expert Insights

Industry experts emphasize the importance of precise claim drafting to avoid issues of patent quality and scope. As noted by Robert Polk Wagner, "the incentives that patent applicants and the Patent Office have to draft and issue, respectively, large quantities of patents with opaque disclosures and indeterminate claims" can lead to challenges in patent enforcement and innovation[3].

Statistics and Market Impact

The market impact of this patent can be gauged by the sales and adoption rates of the pharmaceutical products based on this invention. For instance, entacapone, a key component of the patented composition, has seen significant market growth due to its efficacy in treating Parkinson's disease.

"Many panelists and participants expressed the view that software and Internet patents are impeding innovation," a Federal Trade Commission (FTC) Report summarized, highlighting the broader context of patent quality and innovation[3].

Key Takeaways

  • Specific Claims: The patent's claims are specific to oral compacted compositions containing catechol derivatives and disintegrants.
  • Patent Landscape: The patent is part of a broader landscape involving other oral formulations and delivery systems for Parkinson's disease treatment.
  • Industry Impact: The invention has enhanced treatment outcomes and patient compliance.
  • Legal Proceedings: The patent has been involved in PTAB cases, which test its validity and scope.
  • Metrics for Quality: Narrower claims are associated with higher grant probabilities and shorter examination times.

Frequently Asked Questions (FAQs)

What is the main invention described in U.S. Patent 6,599,530?

The main invention is an oral compacted composition comprising catechol derivatives such as entacapone or nitecapone, along with disintegrants like crospovidone.

What is the significance of the disintegrant in the patent?

The disintegrant, such as crospovidone, facilitates the rapid dissolution of the tablet in the mouth or gastrointestinal tract, enhancing the bioavailability of the active ingredients.

How does this patent impact the treatment of Parkinson's disease?

The patent provides a convenient and effective delivery method for catechol derivatives, improving patient compliance and treatment outcomes for Parkinson's disease.

What are some metrics used to evaluate the quality and scope of patents?

Metrics include independent claim length and count, which are associated with the probability of grant and the duration of the examination process.

Has the patent been involved in any legal proceedings?

Yes, the patent has been involved in cases before the Patent Trial and Appeal Board (PTAB), which have challenged its validity and scope.

Cited Sources

  1. Canadian Patents Database - Patent 2556305 Summary.
  2. Google Patents - U.S. Patent Application 20080139660A1.
  3. Hoover Institution - Patent Claims and Patent Scope.
  4. Google Patents - U.S. Patent 6,599,530.
  5. Law360 - U.S. Patent Number 6,599,530: Ptab Cases.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,599,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.